NCT03690895

Completed

Long-term Outcome of AIDS-related Primary Central Nervous Sy...

Fondation Ophtalmologique Adolphe de Rothschild Source

Compare

Other study identifiers

Sponsor study identifier

NI_2015_2_AMR

Study Type

observational

Actual enrollment (reported)

51

Locations

1 country

Sites

1

Timeline

Study Start

March 15, 2015

Actual (reported)

Primary Completion

October 1, 2016

Actual (reported)

Study Completion

October 1, 2016

Actual (reported)

Brief Summary

This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 51 participants
Study completion date: October 1, 2016
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 15, 2015
Actual (reported)
Primary Completion
October 1, 2016
Actual (reported)
Study Completion
October 1, 2016
Actual (reported)
First Submitted
September 26, 2018
Actual (reported)
First Posted
October 1, 2018
Actual (reported)

Last Updated: October 1, 2018
Status Verified: September 2018
Last Update Submitted: September 28, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

Median duration of survival after diagnosis of lymphoma (years)
At the time of systematic files review (jan 2014) - average follow-up 7 years

Study Arms (1)

Cases

Other: Retrospective survival analysis

Interventions

Retrospective survival analysisOther

Kaplan-Meier model

Cases

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

All patients treated for AIDS-related primary central nervous system lymphoma in Fondation Rothschild (Paris, France) between january1996 and december 2014

You may qualify if:

HIV infection

Sponsors & Collaborators

Fondation Ophtalmologique Adolphe de Rothschild
Research networklead

Study Sites (1)

Fondation Ophtalmologique A. de Rotchschild

Paris, 75019, France

MeSH Terms

Conditions

Lymphoma, AIDS-Related

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Enrollment

51 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: RETROSPECTIVE
Sponsor Type: NETWORK
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 26, 2018

First Posted

October 1, 2018

Study Start

March 15, 2015

Actual (reported)

NCT03684980

LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

Early Phase 1Active Not Recruiting

NCT00967200

Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

Completed

NCT03342586

Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity

Completed

NCT00293475

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 1/2Unknown

NCT05209620

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Phase 2Recruiting

NCT04516655

A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients

Phase 2Unknown

AIDS-related primary central nervous system lymphoma

treated with at least one infusion of methotrexate and combine antiretroviral therapy

You may not qualify if:

prior non-Hodgkin lymphoma

Contact the study team to confirm eligibility.

Primary Completion

October 1, 2016

Actual (reported)

Study Completion

October 1, 2016

Actual (reported)

Last Updated

October 1, 2018

Record last verified: 2018-09

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03690895
Data provider: ClinicalTrials.gov
Source updated: 2018-10-01
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:34:10 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Cases

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations